check

RADNOR, Pa., June 18, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against CareDx, Inc. ("CareDx") (NASDAQ: CDNA). The…

RADNOR, Pa., June 18, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP…

RADNOR, Pa., June 16, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP…

RADNOR, Pa., June 13, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP…

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against CareDx, Inc. (“CareDx”) (NASDAQ: CDNA). The action…

RADNOR, Pa., June 8, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP…

RADNOR, Pa., May 31, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP…

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved both Opdivo ® (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing…

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved both Opdivo ® (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing…

Breyanzi is the only CAR T cell therapy that has been evaluated in two distinct trials in the second-line setting for large B-cell lymphoma, underscoring its value, if approved, as an important treatment option after failure of…